Extended Aromatase Inhibitor Risk/Benefit

Extended Aromatase Inhibitor Risk/Benefit

Aromatase Inhibitors Risk To Benefit Ratio

Breast Cancer Answers®

Managing the Side Effects of Aromatase Inhibitors and Tamoxifen

Community Health Resource Center CPMC

Aromatase Inhibitors: Risks & Benefits For Breast Cancer Patients

Breast Cancer Answers®

How Long Do Aromatase Inhibitor Side Effects Last? All You Need to Know

Yerbba – Breast Cancer

Virtual Pink House: Tamoxifen & Aromatase Inhibitors in ER+ Breast Cancer

Carolina Breast Friends - Breast Cancer Support

Two years of extended anastrazole therapy as effective as five

Benefits of Aromatase Inhibitors After 5 Years of Tamoxifen

Breast Cancer Answers®

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

An Overview of the MA17R Trial in Breast Cancer

Targeted Oncology

Aromatase Inhibitors: A Complete Guide for Breast Cancer Patients

Yerbba – Breast Cancer

Final results of the phase 3 DATA trial assessing aromatase inhibition in HR+ breast cancer

Using Aromatase Inhibitors Longer Than 5 Years

Breast Cancer Answers®

Severe Toxicity to Aromatase Inhibitors for Breast Cancer

Breast Cancer Answers®

Benefits Gained With 5-Year Extended Adjuvant Letrozole Come With a Price

SCS Lunch and Learn: Endocrine Aromatase Inhibitors with Dr. Leslie Klein

Ironwood Cancer & Research Centers

Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast Cancer

Targeted Oncology

Dr. Tripathy on 10 Versus 5 Years of Aromatase Inhibitors

Targeted Oncology

Differential long-term benefit of adjuvant tamoxifen in ER+/HER2- premenopausal + postmenopausal BC

12-year results of anastrozole vs tamoxifen for breast cancer prevention